Skip to main content
VTRS
NASDAQ Life Sciences

Viatris Closes $36.50/Share Pacira Buy as Tender Hits 66.46%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$20.198
Mkt Cap
$23.777B
52W Low
$10.15
52W High
$21.2
52W Position info
99% above low
Off High info
4.7% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

VTRS sits 99% above its 52-week low of $10.15.

Summary

Viatris completed its $36.50-per-share all-cash acquisition of Pacira after the tender offer drew 66.46% of shares, clearing the minimum condition; Pacira is now a wholly owned subsidiary and will be delisted from Nasdaq.


Key Events · M&A and Partnerships · VTRS

  • Tender Offer Closes at 66.46%

    By the November 16, 2026 expiration, 32,929,780 Pacira shares had been validly tendered and not withdrawn, representing approximately 66.46% of shares outstanding and satisfying the minimum condition.

  • Merger Completed Without Pacira Vote

    On November 17, 2026, Viatris accepted all tendered shares for payment at $36.50 per share in cash and merged its Peach Purchaser Sub into Pacira under DGCL Section 251(h), making Pacira a wholly owned subsidiary.

  • Delisting and Deregistration Ahead

    As promptly as practicable after the effective time, Pacira shares will be delisted from the Nasdaq Global Select Market and deregistered under the Exchange Act.

  • Acquired Revenue Guidance $90M-$100M

    For the period from November 17, 2026 through December 31, 2026, Viatris expects the Pacira acquisition to contribute total revenues of between $90 million and $100 million.


Analysis · VTRS · Life Sciences

With 32,929,780 shares tendered — about 66.46% of Pacira's outstanding stock — the minimum condition was cleared when the offer expired on November 16, so Viatris accepted payment on November 17 and immediately completed the merger under Delaware's short-form Section 251(h) provision without a Pacira shareholder vote. Pacira is now a wholly owned Viatris subsidiary, and its shares will be delisted from Nasdaq and deregistered. The deal adds Pacira's non-opioid pain portfolio (EXPAREL, ZILRETTA) and is expected to contribute $90 million to $100 million of revenue in the roughly six weeks remaining in 2026. For Viatris holders the remaining questions are integration and whether the acquired revenue and cost synergies offset the $1.65 billion cash outlay; the outstanding stockholder litigation over Pacira's 14D-9 disclosure did not block closing.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VTRS was trading at $20.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.8B. The 52-week trading range was $10.15 to $21.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VTRS - Latest Insights

VTRS
Nov 12, 2026, 4:16 PM EST
Filing Type: SC TO-T/A
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $20.20 info
Change: -$0.492 (-2%) info
Market Cap: $23.777B info
VTRS
Nov 05, 2026, 9:23 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.40
Real-time Price: $20.20 info
Change: +$0.7976 (+4%) info
Market Cap: $23.777B info
VTRS
Nov 05, 2026, 7:45 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.33
Real-time Price: $20.20 info
Change: +$0.8676 (+4%) info
Market Cap: $23.777B info
VTRS
Nov 05, 2026, 6:59 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.36
Real-time Price: $20.20 info
Change: +$0.8376 (+4%) info
Market Cap: $23.777B info
VTRS
Oct 30, 2026, 7:40 AM EDT
Filing Type: SC TO-T
Importance Score:
8
Price at Filing: $19.30
Real-time Price: $20.20 info
Change: +$0.8976 (+5%) info
Market Cap: $23.777B info